Takeda Q3 Results - Q3 Top Pharma Company Earnings Reports

View Takeda's Q3 Earnings Report

Highlights

  • Consolidated net sales decreased by ¥51.7 billion (6.4%) to ¥755.5 billion over the same period of the previous year.
  • Consolidated operating income increased by ¥157.5 billion (185.2%) to ¥242.5 billion over the same period of the previous year.
  • Consolidated ordinary income increased by ¥153.9 billion (152.4%) to ¥254.9 billion over the same period of the previous year.
  • Consolidated net income increased by ¥117.8 billion (164.2%) to ¥189.6 billion over the same period of the previous year.
  • Consolidated net sales by the Pharmaceuticals segment decrease by ¥47.3 billion (6.2%) to ¥713.1 billion. However, operating income increased by ¥159.9 billion (199.7%) to ¥240.0 billion due to the decrease of selling, general and administrative expenses, which was recorded in the same period of the previous year as in-process R&D expenses in connection with the consolidation of TAP and Millennium as wholly owned subsidiaries

Check out Takeda's current stock quote from CNN Money

Takeda's Website: http://www.takeda.com

Takeda Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

With a seven-figure opioid settlement in the works and its generics unit facing bankruptcy, Mallinckrodt will lean on Acthar Gel for future growth.

After a draft report last November, ICER's final findings on Allergan and Biohaven migraine medicines are more favorable.

As part of a multi-year asset offload, AstraZeneca has divested most of its global rights to constipation med Movantik to RedHill Biopharma.